-
SCANDIC FINANCE ने एलेक्स बोडी को समूह का उपाध्यक्ष नियुक्त किया
-
SCANDIC FINANCE แต่งตั้งอเล็กซ์ โบดี เป็นรองประธานกลุ่มบริษัท
-
SCANDIC FINANCE Grubu, Alex Bodi’yi başkan yardımcılığına atadı
-
Alex Bodi wiceprezesem grupy SCANDIC FINANCE
-
Алекс Боди е назначен за вицепрезидент на групата SCANDIC FINANCE
-
Alex Bodi a SCANDIC FINANCE vállalatcsoport új alelnöke
-
Ο Άλεξ Μπόντι νέος αντιπρόεδρος του ομίλου SCANDIC FINANCE
-
Alex Bodi byl jmenován viceprezidentem skupiny SCANDIC FINANCE
-
Alex Bodi utsedd till vicepresident för SCANDIC FINANCE-koncernen
-
تعيين أليكس بودي نائبًا لرئيس مجموعة SCANDIC FINANCE
-
SCANDIC FINANCEグループ、アレックス・ボディ氏を副社長に任命
-
SCANDIC FINANCE 그룹, 알렉스 보디 부사장 선임
-
亞歷克斯・博迪獲任命為 SCANDIC FINANCE 集團副總裁
-
Jersey Boys Anniversary Tour Opens in Birmingham With Gritty Account of Crime and Fame
-
Алекса Боді призначено віцепрезидентом групи SCANDIC FINANCE
-
Алекс Боди назначен вице-президентом группы SCANDIC FINANCE
-
Alex Bodi appointed Vice President of SCANDIC FINANCE GROUP
-
Alex Bodi, numit vicepreședinte al grupului SCANDIC FINANCE
-
Yealink Summit Addresses AI Governance and Workplace Trust
-
Essential Baking Tools for Christmas Cookie Perfection
-
Elon Musk jokes about moving businesses to space after US midterms
-
West Mercia Police opens 2027 cadet applications to Worcestershire teenagers
-
NHS to test blood screening designed to detect 13 cancers earlier
-
Worcestershire road closures announced for Remembrance Sunday events
-
Democrats near House takeover as voters judge Trump presidency
-
UBC professor describes police call after Galloway remark as act of care
-
Lethbridge submits interest in provincial ground ambulance contract
-
False voting claims spread rapidly during US Election Day
-
The Cat in the Hat expands its stakes to cosmic scale in animated reboot
-
Lettermen co-founder Tony Butala dies at 87
-
Byron Donalds wins Florida governor race and underscores Republican strength
-
James Talarico defeats Ken Paxton in historic Texas Senate result
-
Physicist Claims Alberta Data Center Releases Energy of 23 Atomic Bombs Daily
-
Commentator predicts possible US strike on Iran as regional tensions rise
-
Goa plans relationship-readiness course amid concern over divorces
-
Jordan Bardella's Wealth and Financial Transparency Under Scrutiny
-
Manchester United climbs standings after 3-2 Champions League win over Roma
-
India introduces four-layer motor insurance choice from December 15
-
Mutual fund returns show shifting leaders across market-cap categories
-
Abits Group Highlights Existing Datacenter Infrastructure and 24 MW Power Capacity to Support AI and HPC Hosting Expansion Strategy
-
Cosmos Health's CosmoFarm Begins Commissioning New Automated Order-Processing and Vehicle-Loading Infrastructure, Advancing Capacity That Could Support Over $120 Million in Annual Revenue
-
Horizon Aircraft Signs MOU With Constance Lake First Nation to Bring Lifesaving Medical Aircraft to Remote and Isolated Indigenous Communities
-
BioAdaptives to Acquire Xycota Biosciences to Pursue the Potential of At Home Psilocybin Treatment
-
ATWEC Technologies, Inc. (OTCID:ATWT) Reports August 2026 Revenue of $2.93 Million, Up 17.7% Year-over-Year
-
First Breach Close-Quarters Strike (CQS) Drone Successfully Completes Full Mission Profile
-
NuRAN Targets Africa's Rural Connectivity Opportunity with More Than US$900 Million in Estimated Contract Revenue
-
Jerash Holdings (US), Inc. Declares Quarterly Dividend
-
ReElement Announces $46 Million in Non-Dilutive Federal NMTC Allocation to Support Indiana Critical-Minerals Refining Expansion
-
Dermata Therapeutics Highlights Media Recognition of Tome Skincare Following Commercial Launch
-
Aptevo Achieves Key Clinical Development Objective, Significantly Reducing Infusion-Related Reactions with Mipletamig in Frontline AML
Study on serotonin and depression sparks fierce debate
A controversy in the scientific community over a recent claims anti-depressants can be ineffective at treating depression has highlighted the difficulties in understanding mental health conditions.
One of the prevailing theories currently focuses on serotonin. Depression has been linked to a lack of the molecule, which is involved in transmitting emotions to the brain.
Claims that depression has no link to a chemical imbalance in the brain related to serotonin, casting doubt on the need for anti-depressants, have sparked fierce reaction.
A study by psychiatrists Joanna Moncrieff and Mark Horowitz in the journal Molecular Psychiatry in July concluded that there was no proven link between a lack of serotonin and depression.
The authors said it queried the underlying assumption behind the use of anti-depressants, which are mostly developed to alter serotonin levels, undoing a theory that for decades acted as a framework for research.
The study is based on several previous publications, but it quickly attracted criticism -- particularly its presentation by Moncrieff, known for her scepticism towards biological explanations of depression and her radical stance against the pharmaceutical industry.
"I'm broadly in agreement with the authors' conclusions about our current efforts, though I lack their adamantine certainty," psychiatrist Phil Cowen said on the Science Media Centre website.
"No mental health professional" would endorse the view that a complex condition like depression "stems from a deficiency in a single neurotransmitter", Cowen added.
- 'Mainstream' psychiatry -
Some peers have questioned the methodology, which measured an indirect trace of serotonin rather than taking direct measurements of the molecule.
Moncrieff, who wants to break with what she calls "mainstream" psychiatry, believes the serotonin theory still occupies an important, albeit less prominent, place in the profession.
"Even if leading psychiatrists were beginning to doubt the evidence for depression being related to low serotonin, no one told the public," the British psychiatrist wrote on her blog.
The connection between depression and serotonin is firmly rooted in the popular imagination. French author Michel Houellebecq gave the title "Serotonin" to his 2019 novel in which the main character is depressed.
Moncrieff's undermining of the serotonin theory to argue against current anti-depressants, going beyond the conclusions of her own study, has sparked the most vehement criticism.
Swiss psychiatrist Michel Hofmann told AFP her study was "serious" and contributed to expert debates about depression.
"But I don't think it is an article that should have any impact in the short term on the prescription of anti-depressants," he said.
Moncrieff has warned that anti-depressant treatment should not be suddenly interrupted. But for her, the benefits of a course of anti-depressants are doubtful if it is based on a discredited theory.
But many stress that the effectiveness of the treatments has been scientifically assessed, irrespective of the primary cause of depression.
The medicines used to treat depression "are usually many and ultimately, in most cases, we don't know what exactly makes a treatment effective", Hofmann added.
Debates on the role of serotonin only illustrate how difficult it is to understand the biological and social workings of an illness as complex as depression.
The challenges are forcing researchers to move away from models that are incomplete by their very nature.
"We are still at theories and we continue to search and test models against each other," Hofmann said.
T.Perez--AT